Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ADC Therapeutics (ADCT) EBT (2019 - 2026)

ADC Therapeutics has reported EBT over the past 8 years, most recently at -$33.0 million for Q1 2026.

  • Quarterly results put EBT at -$33.0 million for Q1 2026, up 14.23% from a year ago — trailing twelve months through Mar 2026 was -$167.8 million (down 2.56% YoY), and the annual figure for FY2022 was -$154661.0, up 38.51%.
  • EBT reached -$33.0 million in Q1 2026 per ADCT's latest filing, up from -$41.0 million in the prior quarter.
  • Across five years, EBT topped out at -$20190.0 in Q4 2022 and bottomed at -$65.3 million in Q2 2022.
  • Median EBT over the past 5 years was -$44.5 million (2023), compared with a mean of -$41.8 million.
  • The largest annual shift saw EBT skyrocketed 65.32% in 2022 before it tumbled 234.74% in 2023.
  • Over 5 years, EBT stood at -$20190.0 in 2022, then tumbled by 224763.79% to -$45.4 million in 2023, then rose by 3.92% to -$43.6 million in 2024, then rose by 6.08% to -$41.0 million in 2025, then grew by 19.52% to -$33.0 million in 2026.
  • Business Quant data shows EBT for ADCT at -$33.0 million in Q1 2026, -$41.0 million in Q3 2025, and -$55.4 million in Q2 2025.